600713 南京医药
已收盘 12-31 15:00:00
资讯
新帖
简况
南京医药最新公告：拟1.2亿元参设南药医疗器械投资公司
证券之星 · 2025-12-18
南京医药最新公告：拟1.2亿元参设南药医疗器械投资公司
南京医药最新公告：控股子公司拟3.98亿元投建现代医药物流扩建项目
中金财经 · 2025-12-10
南京医药最新公告：控股子公司拟3.98亿元投建现代医药物流扩建项目
南京医药（600713）披露股份性质变更暨2025年限制性股票激励计划预留授予进展公告，12月05日股价上涨0.58%
证券之星 · 2025-12-05
南京医药（600713）披露股份性质变更暨2025年限制性股票激励计划预留授予进展公告，12月05日股价上涨0.58%
南京医药（600713）披露公司全称、注册资本变更登记及《公司章程》备案完成公告，12月03日股价上涨0.97%
证券之星 · 2025-12-03
南京医药（600713）披露公司全称、注册资本变更登记及《公司章程》备案完成公告，12月03日股价上涨0.97%
南京医药（600713）39.91万股限售股将于11月28日解禁，占总股本0.03%
证券之星 · 2025-11-28
南京医药（600713）39.91万股限售股将于11月28日解禁，占总股本0.03%
南京医药（600713）披露2025年限制性股票激励计划预留授予结果，11月21日股价下跌3.12%
证券之星 · 2025-11-21
南京医药（600713）披露2025年限制性股票激励计划预留授予结果，11月21日股价下跌3.12%
南京医药（600713）披露增补第十届董事会非独立董事议案获通过，11月19日股价下跌1.15%
证券之星 · 2025-11-19
南京医药（600713）披露增补第十届董事会非独立董事议案获通过，11月19日股价下跌1.15%
每周股票复盘：南京医药（600713）拟取消监事会并更名
证券之星 · 2025-11-16
每周股票复盘：南京医药（600713）拟取消监事会并更名
南京医药（600713）披露拟取消监事会并变更公司名称，11月11日股价上涨0.38%
证券之星 · 2025-11-11
南京医药（600713）披露拟取消监事会并变更公司名称，11月11日股价上涨0.38%
每周股票复盘：南京医药（600713）控股股东减持南药转债10.17%
证券之星 · 2025-11-09
每周股票复盘：南京医药（600713）控股股东减持南药转债10.17%
南京医药（600713）披露控股股东减持可转换公司债券进展公告，11月05日股价上涨0.39%
证券之星 · 2025-11-05
南京医药（600713）披露控股股东减持可转换公司债券进展公告，11月05日股价上涨0.39%
每周股票复盘：南京医药（600713）Q3净利降15.22%
证券之星 · 2025-11-02
每周股票复盘：南京医药（600713）Q3净利降15.22%
南京医药（600713）2025年三季报简析：增收不增利
证券之星 · 2025-11-01
南京医药（600713）2025年三季报简析：增收不增利
图解南京医药三季报：第三季度单季净利润同比下降15.22%
证券之星 · 2025-10-30
图解南京医药三季报：第三季度单季净利润同比下降15.22%
南京医药（600713）披露召开2025年第二次临时股东大会公告，10月30日股价下跌0.39%
证券之星 · 2025-10-30
南京医药（600713）披露召开2025年第二次临时股东大会公告，10月30日股价下跌0.39%
南京医药（600713）披露股份回购实施结果暨股份变动的公告，10月24日股价下跌0.2%
证券之星 · 2025-10-24
南京医药（600713）披露股份回购实施结果暨股份变动的公告，10月24日股价下跌0.2%
每周股票复盘：南京医药（600713）控股股东减持南药转债10.25%
证券之星 · 2025-10-19
每周股票复盘：南京医药（600713）控股股东减持南药转债10.25%
南京医药（600713）披露公司董事离任公告，10月17日股价下跌1.0%
证券之星 · 2025-10-17
南京医药（600713）披露公司董事离任公告，10月17日股价下跌1.0%
南京医药：公司董事离任
证券日报 · 2025-10-17
南京医药：公司董事离任
南京医药（600713）披露控股股东减持可转换公司债券进展公告，10月15日股价上涨0.4%
证券之星 · 2025-10-15
南京医药（600713）披露控股股东减持可转换公司债券进展公告，10月15日股价上涨0.4%
加载更多
公司概况
公司名称：
南京医药集团股份有限公司
所属行业：
零售业
上市日期：
1996-07-01
主营业务：
南京医药集团股份有限公司的主营业务是医药批发、医药零售、医药“互联网+”业务以及医药第三方物流服务业务。公司的主要产品是医药批发、医药零售、医药“互联网+”、医药第三方物流服务业务。公司亦曾荣获“全国医药流通创新示范企业”称号，是第一批“全国供应链创新与应用示范企业”。
发行价格：
5.98
{"stockData":{"symbol":"600713","market":"SH","secType":"STK","nameCN":"南京医药","latestPrice":5.46,"timestamp":1767164400000,"preClose":5.38,"halted":0,"volume":19784538,"delay":0,"changeRate":0.0149,"floatShares":1285000000,"shares":1309000000,"eps":0.4055,"marketStatus":"已收盘","change":0.08,"latestTime":"12-31 15:00:00","open":5.45,"high":5.55,"low":5.33,"amount":107000000,"amplitude":0.0409,"askPrice":5.47,"askSize":2287,"bidPrice":5.46,"bidSize":93,"shortable":0,"etf":0,"ttmEps":0.4055,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.38,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":5.92,"lowLimit":4.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1308931240,"isCdr":false,"pbRate":1.03,"roa":"--","peRate":13.464858,"roe":"5.79%","epsLYR":0.438,"committee":-0.262228,"marketValue":7147000000,"turnoverRate":0.0154,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","floatMarketCap":7018000000},"requestUrl":"/m/hq/s/600713","defaultTab":"news","newsList":[{"id":"2592743559","title":"南京医药最新公告：拟1.2亿元参设南药医疗器械投资公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2592743559","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592743559?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:52","pubTimestamp":1766051533,"startTime":"0","endTime":"0","summary":"南京医药公告称，公司拟与南京新工新兴产业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业共同投资设立南京新工南药医疗器械强链并购股权投资有限责任公司，其中公司拟出资1.2亿元，占南药医疗器械投资公司认缴出资总额的59.9%。南药医疗器械投资公司成立后，专项用于投资宁波江丰生物信息技术有限公司。南药医疗器械投资公司将以江丰生物整体估值不超过7.5亿元为前提受让江丰生物约22.5%的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","09997","BK1222","BK0250","BK1583","600713","BK0209","BK1100","BK1574","159883"],"gpt_icon":0},{"id":"2590583739","title":"南京医药最新公告：控股子公司拟3.98亿元投建现代医药物流扩建项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583739","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583739?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:56","pubTimestamp":1765360587,"startTime":"0","endTime":"0","summary":"南京医药(600713.SH)公告称，公司控股子公司安徽天星拟投资建设现代医药物流扩建项目，对一期地块已建成的1#物流库进行部分设备改造、新建二期医药物流仓储建筑及配套设施。项目位于安徽省合肥市经济技术开发区，慈光路以北、宿松路以西区域，新建建筑面积58518.7m2，建设工期约2.92年(共35个月)，总投资不超过3.98亿元。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251210/31856725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","BK1161","09939","600713","BK1515","BK0209","BK1574","BK0250"],"gpt_icon":0},{"id":"2589813308","title":"南京医药（600713）披露股份性质变更暨2025年限制性股票激励计划预留授予进展公告，12月05日股价上涨0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589813308","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589813308?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:24","pubTimestamp":1764944666,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘，南京医药报收于5.22元，较前一交易日上涨0.58%，最新总市值为68.33亿元。公司近日发布公告称，南京医药集团股份有限公司于2025年11月21日向29名激励对象预留授予194.10万股限制性股票，授予价格为2.54元/股。截至2025年11月25日，激励对象已完成缴款，认购股款合计4,930,140.00元。相关股份已由无限售条件的流通股变更为有限售条件的流通股，公司股本结构相应调整。后续将办理登记手续并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0},{"id":"2588704258","title":"南京医药（600713）披露公司全称、注册资本变更登记及《公司章程》备案完成公告，12月03日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588704258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588704258?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:21","pubTimestamp":1764771681,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，南京医药报收于5.22元，较前一交易日上涨0.97%，最新总市值为68.33亿元。该股当日开盘5.17元，最高5.28元，最低5.13元，成交额达1.27亿元，换手率为1.89%。近日，南京医药发布公告称，公司已完成公司全称、注册资本变更登记及《公司章程》备案。注册资本变更为1,308,929,289元。此次变更系因可转换公司债券转股及公司治理结构调整所致，相关议案已获董事会和股东大会审议通过，并取得南京市市场监督管理局核发的营业执照。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300040355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0250","600713"],"gpt_icon":0},{"id":"2586751512","title":"南京医药（600713）39.91万股限售股将于11月28日解禁，占总股本0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586751512","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586751512?lang=zh_cn&edition=full","pubTime":"2025-11-28 08:06","pubTimestamp":1764288361,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，南京医药于11月28日将有39.91万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.03%。最近一年内，该股累计解禁2.56亿股，占总股本的19.53%。本次解禁后，公司还有2162.57万股限售股份，占总股本1.65%。南京医药主营业务：医药批发、医药零售、医药“互联网+”以及医药第三方物流服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800003302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0250","600713"],"gpt_icon":0},{"id":"2585141848","title":"南京医药（600713）披露2025年限制性股票激励计划预留授予结果，11月21日股价下跌3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585141848?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:35","pubTimestamp":1763735720,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，南京医药报收于4.97元，较前一交易日下跌3.12%，最新总市值为65.05亿元。该股当日开盘5.1元，最高5.12元，最低4.96元，成交额达8549.24万元，换手率为1.32%。近日，南京医药发布关于向2025年限制性股票激励计划激励对象预留授予限制性股票的公告。公告显示，公司已于2025年11月21日向29名核心管理及骨干人员预留授予194.10万股限制性股票，授予价格为2.54元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600713","BK0209","BK0250"],"gpt_icon":0},{"id":"2584094781","title":"南京医药（600713）披露增补第十届董事会非独立董事议案获通过，11月19日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584094781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584094781?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:24","pubTimestamp":1763562262,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，南京医药报收于5.15元，较前一交易日下跌1.15%，最新总市值为67.41亿元。根据公司近日发布的公告，南京医药于2025年11月19日召开2025年第二次临时股东大会，审议通过了包括修订公司章程、股东大会议事规则、董事会议事规则、企业负责人薪酬与绩效考核管理办法在内的多项议案，并同意增补第十届董事会非独立董事。出席会议的股东所持表决权股份占公司总股本的56.1457%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900040013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0},{"id":"2583651699","title":"每周股票复盘：南京医药（600713）拟取消监事会并更名","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651699?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:24","pubTimestamp":1763234654,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，南京医药报收于5.33元，较上周的5.15元上涨3.5%。本周，南京医药11月14日盘中最高价报5.38元。本周关注点公司公告汇总：南京医药拟修订公司章程，取消监事会，由董事会审计与风险控制委员会行使监事会职权。公司公告汇总：公司全称拟变更为南京医药集团股份有限公司，注册资本因可转债转股增至1,308,929,289元。南京医药股份有限公司将于2025年11月19日召开2025年第二次临时股东大会，会议采取现场投票与网络投票相结合的方式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600713","BK0209","BK0250"],"gpt_icon":0},{"id":"2582354245","title":"南京医药（600713）披露拟取消监事会并变更公司名称，11月11日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582354245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582354245?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:27","pubTimestamp":1762853268,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，南京医药报收于5.22元，较前一交易日上涨0.38%，最新总市值为68.33亿元。该股当日开盘5.2元，最高5.23元，最低5.15元，成交额达5931.05万元，换手率为0.89%。近日，南京医药发布《2025年第二次临时股东大会材料》公告，宣布拟对多项公司治理结构进行调整。根据公告内容，公司拟修订公司章程，取消监事会，相关职权由董事会审计与风险控制委员会行使；公司全称拟变更为南京医药集团股份有限公司；因可转债转股，注册资本将增至1,308,929,289元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100028402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","600713","BK0209"],"gpt_icon":0},{"id":"2582184861","title":"每周股票复盘：南京医药（600713）控股股东减持南药转债10.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582184861","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582184861?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:58","pubTimestamp":1762631894,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，南京医药报收于5.15元，较上周的5.06元上涨1.78%。本周，南京医药11月7日盘中最高价报5.17元。本周关注点公司公告汇总：控股股东新工投资集团减持南药转债1,100,410张，占发行总量的10.17%。公司公告汇总：本次减持后，新工投资集团持有南药转债比例降至13.69%。此前，新工投资集团已于2025年9月1日至10月14日期间减持2,189,500张，占发行总量的20.25%。新工投资集团原通过优先配售认购4,770,210张，占发行总量的44.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600713","BK0209","BK0250"],"gpt_icon":0},{"id":"2581750017","title":"南京医药（600713）披露控股股东减持可转换公司债券进展公告，11月05日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581750017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581750017?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:28","pubTimestamp":1762352898,"startTime":"0","endTime":"0","summary":"近日，南京医药发布关于控股股东减持公司可转换公司债券的进展公告。公告显示，公司控股股东南京新工投资集团有限责任公司于2025年10月16日至11月4日期间通过上海证券交易所系统累计减持“南药转债”1,100,410张，占可转债发行总量的10.17%。本次减持后，南京新工投资集团持有“南药转债”1,480,300张，占发行总量的13.69%。目前“南药转债”发行总额为108,149.10万元，债券代码为110098，存续期自2024年12月25日起至2030年12月24日止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0},{"id":"2580940581","title":"每周股票复盘：南京医药（600713）Q3净利降15.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580940581","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580940581?lang=zh_cn&edition=full","pubTime":"2025-11-02 10:07","pubTimestamp":1762049229,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，南京医药报收于5.06元，较上周的5.11元下跌0.98%。本周，南京医药10月27日盘中最高价报5.14元。公司公告汇总：南京医药将召开2025年第二次临时股东大会，审议修订公司章程等五项议案。股本股东变化截至2025年9月30日，南京医药股东户数为5.16万户，较6月30日减少911户，减幅1.73%。业绩披露要点2025年前三季度，南京医药主营收入411.35亿元，同比上升0.48%；归母净利润4.02亿元，同比下降9.03%；扣非净利润3.71亿元，同比下降14.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0},{"id":"2580414773","title":"南京医药（600713）2025年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2580414773","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580414773?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:13","pubTimestamp":1761948839,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期南京医药发布2025年三季报。根据财报显示，南京医药增收不增利。截至本报告期末，公司营业总收入411.35亿元，同比上升0.48%，归母净利润4.02亿元，同比下降9.03%。按单季度数据看，第三季度营业总收入131.68亿元，同比下降3.93%，第三季度归母净利润1.11亿元，同比下降15.22%。本次财报公布的各项数据指标表现一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100005607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600713","BK0209","BK0250"],"gpt_icon":0},{"id":"2579484131","title":"图解南京医药三季报：第三季度单季净利润同比下降15.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579484131","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579484131?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:24","pubTimestamp":1761823483,"startTime":"0","endTime":"0","summary":"证券之星消息，南京医药2025年三季报显示，前三季度公司主营收入411.35亿元，同比上升0.48%；归母净利润4.02亿元，同比下降9.03%；扣非净利润3.71亿元，同比下降14.78%；其中2025年第三季度，公司单季度主营收入131.68亿元，同比下降3.93%；单季度归母净利润1.11亿元，同比下降15.22%；单季度扣非净利润1.09亿元，同比下降16.42%；负债率76.62%，投资收益114.4万元，财务费用3.46亿元，毛利率5.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000039904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600713"],"gpt_icon":0},{"id":"2579116538","title":"南京医药（600713）披露召开2025年第二次临时股东大会公告，10月30日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579116538","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579116538?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:59","pubTimestamp":1761818361,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，南京医药报收于5.05元，较前一交易日下跌0.39%，最新总市值为66.1亿元。该股当日开盘5.06元，最高5.1元，最低5.04元，成交额达4372.82万元，换手率为0.67%。公司近日发布公告，宣布将于2025年11月19日14:00在南京市雨花台区安德门大街55号2幢8层会议室召开2025年第二次临时股东大会，采用现场投票与网络投票相结合方式，网络投票通过上海证券交易所系统进行，时间为当日9:15-15:00。股权登记日为2025年11月11日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000035469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0},{"id":"2577591312","title":"南京医药（600713）披露股份回购实施结果暨股份变动的公告，10月24日股价下跌0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577591312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577591312?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:30","pubTimestamp":1761298256,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，南京医药股份有限公司于2025年3月14日召开董事会，审议通过以集中竞价交易方式回购股份的方案，回购期限为2025年3月14日至2026年3月14日，拟回购金额为7,000万元至13,158万元，回购价格不超过7.31元/股，用于实施2025年限制性股票激励计划。其中1,601.90万股已用于2025年限制性股票激励计划首次授予，剩余198.0852万股存放于回购专用证券账户，后续将用于股权激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400031570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0},{"id":"2576041187","title":"每周股票复盘：南京医药（600713）控股股东减持南药转债10.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041187","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041187?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:26","pubTimestamp":1760819169,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：控股股东新工投资集团减持“南药转债”1,108,000张，占发行总量10.25%。南京医药关于控股股东减持公司可转换公司债券的进展公告南京医药股份有限公司于近日收到控股股东南京新工投资集团有限责任公司通知，新工投资集团在2025年9月16日至10月14日期间通过上交所系统累计减持“南药转债”1,108,000张，占可转债发行总量的10.25%。本次减持前，新工投资集团持有3,688,710张，占发行总量34.11%；减持后持有2,580,710张，占发行总量23.86%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","600713","BK0209"],"gpt_icon":0},{"id":"2576405198","title":"南京医药（600713）披露公司董事离任公告，10月17日股价下跌1.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576405198","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576405198?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:44","pubTimestamp":1760712252,"startTime":"0","endTime":"0","summary":"近日，南京医药发布关于公司董事离任的公告。公告称，非独立董事陆志虹先生因有其他工作安排，申请辞去公司第十届董事会董事、董事会审计与风险控制委员会、薪酬与绩效考核委员会委员职务，辞职自2025年10月17日起生效。公司董事会将按相关规定尽快履行增补非独立董事的程序。陆志虹先生不存在未履行完毕的公开承诺，已做好工作交接，且截至公告披露日未持有公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600713","BK0250","BK0209"],"gpt_icon":0},{"id":"2576030362","title":"南京医药：公司董事离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2576030362","media":"证券日报 ","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576030362?lang=zh_cn&edition=full","pubTime":"2025-10-17 20:11","pubTimestamp":1760703060,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月17日晚间，南京医药发布公告称，公司董事会收到非独立董事陆志虹先生提交的书面辞职报告，陆志虹先生申请辞去公司第十届董事会董事、董事会审计与风险控制委员会、薪酬与绩效考核委员会委员职务，辞去上述职务后不在公司担任任何职务。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-17/doc-infufcyk8609556.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-17/doc-infufcyk8609556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600713","BK0209","BK0250"],"gpt_icon":0},{"id":"2575369697","title":"南京医药（600713）披露控股股东减持可转换公司债券进展公告，10月15日股价上涨0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575369697","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575369697?lang=zh_cn&edition=full","pubTime":"2025-10-15 22:39","pubTimestamp":1760539150,"startTime":"0","endTime":"0","summary":"截至2025年10月15日收盘，南京医药报收于5.03元，较前一交易日上涨0.4%，最新总市值为65.84亿元。公司近日发布公告称，控股股东南京新工投资集团有限责任公司于2025年9月16日至10月14日期间通过上海证券交易所系统累计减持“南药转债”1,108,000张，占可转债发行总量的10.25%。本次减持后，新工投资集团持有“南药转债”2,580,710张，占发行总量的23.86%。南药转债发行总额为108,149.10万元，共计10,814,910张，债券代码为110098，存续期自2024年12月25日起至2030年12月24日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500038442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","600713","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767328738960,"stockEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.0727},{"period":"3month","weight":0.1053},{"period":"6month","weight":0.0561},{"period":"1year","weight":0.138},{"period":"ytd","weight":0.138}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"51638人(较上一季度减少1.73%)","perCapita":"24891股","listingDate":"1996-07-01","address":"江苏省南京市雨花台区安德门大街55号2幢","registeredCapital":"130893万元","survey":" 南京医药集团股份有限公司的主营业务是医药批发、医药零售、医药“互联网+”业务以及医药第三方物流服务业务。公司的主要产品是医药批发、医药零售、医药“互联网+”、医药第三方物流服务业务。公司亦曾荣获“全国医药流通创新示范企业”称号，是第一批“全国供应链创新与应用示范企业”。","listedPrice":5.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南京医药(600713)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南京医药(600713)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南京医药,600713,南京医药股票,南京医药股票老虎,南京医药股票老虎国际,南京医药行情,南京医药股票行情,南京医药股价,南京医药股市,南京医药股票价格,南京医药股票交易,南京医药股票购买,南京医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南京医药(600713)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南京医药(600713)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}